Sharechat Logo

Volpara Health to raise A$18 mln to fund US, Asian expansion

Monday 30th April 2018

Text too small?

ASX-listed Volpara Health Technologies is raising A$18 million through a placement to institutional investors and a share purchase plan to speed up growth in the US and fund the rollout of direct sales into Asia. 

 

Wellington-based Volpara, which focuses on early detection of breast cancer using artificial intelligence, is raising A$15 million selling shares in a placement at 60 Australian cents apiece to institutional investors, a 13 percent discount to the last trading price before the shares were halted. It plans to raise another A$3 million from existing shareholders, who will be able to buy up to A$15,000 of shares at the same price. 

 

The health-tech company's cash on hand will rise to A$21.8 million from A$4.6 million once the capital raising is completed, and comes after Volpara's operational cash outflow narrowed to NZ$7.7 million in the year ended March 31 from NZ$8.2 million a year earlier. 

 

Volpara's earmarked some NZ$9 million to expand its US direct sales, marketing and customers teams to accelerate sales growth with a view to delivering 9 percent market share by the end of the 2019 financial year. An additional NZ$4 million will develop new features in an effort to boost the firm's fee per woman, while NZ$2 million will begin the rollout of direct sales into Asia, a rapidly growing market. That will leave the company with NZ$3 million of working capital. 

 

The placement is expected to settle on May 4 while the share purchase plan will run from May 7 to May 25. The allotment will take place May 31. 

 

Morgans Corporate and Bell Potter Securities have been appointed the joint lead managers. 

 

Volpara said it's achieved regulatory clearances for Japan, Taiwan, Australia and South Korea. Part of the capital raise will be used to target private hospital chains, find the right distribution partners and ensure Volpara is in government-run trials as necessary, it said. 

 

Separately the company said its cash position was NZ$4.8 million in the final quarter of the year to March and its receipts from customers reached NZ$3.07 million in the 12-month period, the first time they have surpassed NZ$3 million. It holds no debt. 

 

"This has been our best sales quarter to date. We aimed high, setting ambitious milestones for the year, which we've met both in terms of ARR (annualised recurring revenue) and US market penetration, now at NZ$3.6 million and 3.2 percent respectively," said Volpara chief executive Ralph Highnam. 

 

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares rise; trading quiet ahead of upcoming earnings
NZ dollar firms against the Aussie heading into federal election
Fletcher-commissioned Deloitte report shows building material costs are low
RBNZ censures ANZ, prescribes risk capital calculation
RBNZ censures ANZ, prescribes risk capital calculation
SeaDragon shareholders back $4M injection to stave off liquidation
SeaDragon shareholders back $4M injection to stave off liquidation
Businesses get some reprieve in March quarter on cheaper prices
NZ manufacturing activity expands on month in April but down on year
Xero's CEO says it still has a cautious future in the US

IRG See IRG research reports